MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF
Go back to MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF| Mannkind Corporation (NASDAQ: MNKD) | Delayed: 3.89 -0.05 (1.27%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.94 | 52 Week High | $2.51 | |||
| Open | $3.95 | 52 Week Low | $0.41 | |||
| Day High | $4.06 | P/E | N/A | |||
| Day Low | $3.88 | EPS | $-0.64 | |||
| Volume | 3,562,816 | |||||
| Mannkind Corporation (NASDAQ: MNKD) | Delayed: 3.89 -0.05 (1.27%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.94 | 52 Week High | $2.51 | |||
| Open | $3.95 | 52 Week Low | $0.41 | |||
| Day High | $4.06 | P/E | N/A | |||
| Day Low | $3.88 | EPS | $-0.64 | |||
| Volume | 3,562,816 | |||||
